CD19 and leukemia: It does, however, appear as if the dose per se does not dramatically impact the formation of CD19+ cells in mice [8, 9] or induce leukemia, unless combined with additional oncogenic events such as expression of a constitutively active STAT5 [11] or heterozygote deletion of Ebf [10] in mouse models.